For example, FOXA2 is a tumour suppressor and inhibitor of EMT in human lung cancers [57, 93] and reduced FOXA2 expression in hepatocellular carcinoma (HCC) is associated with worse clinical outcome. Here, FOXA2 is linked to neoplasm.